Merck & Co., Inc. (MRK) Position Lifted by Nicola Wealth Management LTD.

[ad_1]

Nicola Wealth Management LTD. increased its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 10.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 85,700 shares of the company’s stock after acquiring an additional 8,200 shares during the period. Nicola Wealth Management LTD.’s holdings in Merck & Co., Inc. were worth $5,789,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Mckinley Capital Management LLC Delaware lifted its position in shares of Merck & Co., Inc. by 5.6% in the second quarter. Mckinley Capital Management LLC Delaware now owns 15,447 shares of the company’s stock valued at $938,000 after acquiring an additional 815 shares in the last quarter. Summit X LLC lifted its position in shares of Merck & Co., Inc. by 9.2% in the first quarter. Summit X LLC now owns 10,093 shares of the company’s stock valued at $552,000 after acquiring an additional 850 shares in the last quarter. Covenant Asset Management LLC lifted its position in shares of Merck & Co., Inc. by 1.4% in the second quarter. Covenant Asset Management LLC now owns 62,353 shares of the company’s stock valued at $3,785,000 after acquiring an additional 850 shares in the last quarter. First Midwest Bank Trust Division lifted its position in shares of Merck & Co., Inc. by 2.1% in the second quarter. First Midwest Bank Trust Division now owns 42,242 shares of the company’s stock valued at $2,564,000 after acquiring an additional 869 shares in the last quarter. Finally, Pegasus Asset Management Inc. lifted its position in shares of Merck & Co., Inc. by 4.2% in the first quarter. Pegasus Asset Management Inc. now owns 21,794 shares of the company’s stock valued at $1,187,000 after acquiring an additional 873 shares in the last quarter. Institutional investors own 72.19% of the company’s stock.

Several equities analysts recently weighed in on MRK shares. Zacks Investment Research downgraded Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research report on Wednesday, May 16th. TheStreet upgraded Merck & Co., Inc. from a “c+” rating to a “b-” rating in a research report on Friday, June 8th. Jefferies Financial Group reiterated a “hold” rating and set a $59.00 target price on shares of Merck & Co., Inc. in a research report on Sunday, July 15th. BMO Capital Markets reiterated a “buy” rating and set a $70.00 target price on shares of Merck & Co., Inc. in a research report on Sunday, July 22nd. Finally, Bank of America increased their target price on Merck & Co., Inc. from $70.00 to $74.00 and gave the stock a “buy” rating in a research report on Monday, July 30th. Six research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $67.93.

NYSE MRK opened at $69.86 on Thursday. The stock has a market cap of $186.25 billion, a P/E ratio of 16.45, a price-to-earnings-growth ratio of 2.38 and a beta of 0.81. The company has a current ratio of 1.33, a quick ratio of 1.04 and a debt-to-equity ratio of 0.61. Merck & Co., Inc. has a twelve month low of $52.83 and a twelve month high of $70.59.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Friday, July 27th. The company reported $1.06 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.03 by $0.03. The company had revenue of $10.47 billion during the quarter, compared to analyst estimates of $10.28 billion. Merck & Co., Inc. had a return on equity of 32.68% and a net margin of 3.67%. The firm’s revenue was up 5.4% on a year-over-year basis. During the same period in the prior year, the firm posted $1.01 earnings per share. equities analysts anticipate that Merck & Co., Inc. will post 4.27 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Friday, October 5th. Shareholders of record on Monday, September 17th will be paid a dividend of $0.48 per share. The ex-dividend date of this dividend is Friday, September 14th. This represents a $1.92 annualized dividend and a yield of 2.75%. Merck & Co., Inc.’s dividend payout ratio is presently 48.24%.

In other Merck & Co., Inc. news, Chairman Kenneth C. Frazier sold 228,091 shares of the company’s stock in a transaction dated Tuesday, July 31st. The stock was sold at an average price of $65.00, for a total transaction of $14,825,915.00. Following the completion of the sale, the chairman now directly owns 938,788 shares in the company, valued at $61,021,220. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Adam H. Schechter sold 134,094 shares of the company’s stock in a transaction dated Monday, June 18th. The stock was sold at an average price of $61.00, for a total value of $8,179,734.00. Following the sale, the executive vice president now owns 100,000 shares of the company’s stock, valued at $6,100,000. The disclosure for this sale can be found here. Insiders have sold 396,393 shares of company stock valued at $25,235,061 over the last 90 days. 0.32% of the stock is currently owned by insiders.

Merck & Co., Inc. Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

See Also: Book Value Per Share in Stock Trading

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Merck & Co. Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.

[ad_2]

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *